TY  - JOUR
AU  - Barnett, Gillian C
AU  - Kerns, Sarah L
AU  - Dorling, Leila
AU  - Fachal, Laura
AU  - Aguado-Barrera, Miguel E
AU  - Martínez-Calvo, Laura
AU  - Jandu, Harkeran K
AU  - Welsh, Ceilidh
AU  - Tyrer, Jonathan
AU  - Coles, Charlotte E
AU  - Haviland, Joanne S
AU  - Parker, Christopher
AU  - Gómez-Caamaño, Antonio
AU  - Calvo-Crespo, Patricia
AU  - Sosa-Fajardo, Paloma
AU  - Burnet, Neil G
AU  - Summersgill, Holly
AU  - Webb, Adam
AU  - De Ruysscher, Dirk
AU  - Seibold, Petra
AU  - Chang-Claude, Jenny
AU  - Talbot, Christopher J
AU  - Rattay, Tim
AU  - Parliament, Matthew
AU  - De Ruyck, Kim
AU  - Rosenstein, Barry S
AU  - Pharoah, Paul D P
AU  - Dunning, Alison M
AU  - Vega, Ana
AU  - West, Catharine M L
TI  - No association between polygenic risk scores for cancer and development of radiotherapy toxicity.
JO  - International journal of radiation oncology, biology, physics
VL  - 114
IS  - 3
SN  - 0360-3016
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2022-01495
SP  - 494-501
PY  - 2022
N1  -  2022 Nov 1;114(3):494-501
AB  - To test whether updated polygenic risk scores (PRS) for susceptibility to cancer affect risk of radiotherapy toxicity.Analyses included 9,717 patients with breast (n=3,078), prostate (n=5,748) or lung (n=891) cancer from XXXX and XXXX Consortia cohorts. Patients underwent potentially curative radiotherapy and were assessed prospectively for toxicity. Germline genotyping involved genome-wide single nucleotide polymorphism (SNP) arrays with non-typed SNPs imputed. PRS for each cancer were generated by summing literature-identified cancer susceptibility risk alleles: 352 breast, 136 prostate, 24 lung. Weighted PRS were generated using log odds ratios for cancer susceptibility. Standardized total average toxicity (STAT) scores at 2 and 5 years (breast, prostate) or 6 to 12 months (lung) quantified toxicity. Primary analysis tested late STAT, secondary analyses investigated acute STAT, and individual endpoints and SNPs using multivariable regression.Increasing PRS did not increase risk of late toxicity in patients with breast (OR 1.000, 95
LB  - PUB:(DE-HGF)16
C6  - pmid:35840111
DO  - DOI:10.1016/j.ijrobp.2022.06.098
UR  - https://inrepo02.dkfz.de/record/180699
ER  -